EU is Taking AstraZeneca to Court Over Vaccine Issues

Since then, the company has amended the delivery of the first 100 million doses to the end of June, which is just a third of what it had originally promised. Now, the EU is trying to distance itself from AstraZeneca as it prepares legal proceedings against the firm. The company’s CEO Pascal Soriot claims the supply contracts say the company will make its “best effort” to deliver, and that the deals didn’t require deliveries of specific numbers on a set timeline. Last week, Reuters reported that the EU won’t exercise its options for 300 million AstraZeneca doses, and will instead move to Prizer and Moderna.